Results 221 to 230 of about 1,084,074 (266)

Predicting Ligand Binding Modes by Scaffold-Guided Structure Refinement. [PDF]

J Med Chem
Pletzer-Zelgert J, Rarey M, Kuhn B.
europepmc   +1 more source

Cellular Logistics and Synaptic Vesicle Vulnerability in Major Depressive Disorder and Amyotrophic Lateral Sclerosis Comorbidity: Insights From Nicotinamide Mononucleotide Rescue and Transcriptome-Wide Association Study Integration. [PDF]

Cureus
Cheung N.
europepmc   +1 more source

Chemokine Ligand-3 (CCL3) as a Novel Mediator of Inflammatory Bowel Disease Activity. [PDF]

Gastro Hep Adv
O'Brien E, Fine K, Sienkiewicz O, Wei Y, Orr CE, Mulder DJ.   +5 more
europepmc   +1 more source

Therapeutic Osteoinductive Potential of Saposhnikovia divaricata Schischkin in a Mouse Drill-Hole Bone Defect Model. [PDF]

Adv Biol (Weinh)
Kim H, Hong JY, Kim H, Yeo C, Jeon WJ, Lee J, Lee YJ, Ha IH.   +7 more
europepmc   +1 more source

Pocket-Surface Discrete Differential Geometry as a Leakage-Robust Feature Class for Protein-Ligand Binding Affinity Prediction. [PDF]

Molecules
Balcı MA, Çetin E, Calibasi-Kocal G, Akgüller Ö.   +3 more
europepmc   +1 more source

Estrogens and the osteoprotegerin/RANK-ligand system

, 2018
Hofbauer, L. C., Viereck, Volker
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

RANK Ligand: Effects of Inhibition

Current Oncology Reports, 2010
Receptor activator of nuclear factor kappa-light-chain-enhancer of activated B-cells (RANK) and its ligand (RANKL) belong to the tumor necrosis factor (TNF) superfamily. RANK mRNA is expressed widely in bone and bone marrow. It has a significant role in stimulating osteoclast differentiation and maturation, and also in preventing apoptosis.
Saby George, Andrew Brenner, John Sarantopoulos   +2 more
exaly   +3 more sources

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

Clinical Therapeutics, 2012
Postmenopausal osteoporosis results from bone loss and decreased bone strength mediated by an increased rate of bone remodeling secondary to reduced estrogen levels. Remodeling cycles are initiated by osteoclasts, the formation, function, and survival of which depend on RANK ligand (RANKL).
David Dempster
exaly   +3 more sources

RANK ligand inhibition with denosumab for the management of osteoporosis

Expert Opinion on Biological Therapy, 2006
Receptor activator of nuclear factor-kappaB ligand (RANKL) is a cytokine member of the tumour necrosis factor family that is the principal final mediator of osteoclastic bone resorption. It plays a major role in the pathogenesis of postmenopausal osteoporosis, as well bone loss associated with rheumatoid arthritis, metastatic cancer, multiple myeloma ...
E Michael Lewiecki
exaly   +3 more sources